Barclays
BIOA icon

Barclays’s BioAge Labs BIOA Stock Holding History

Barclays’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$162K Sell
22,891
-2,729
-11% -$37.8K ﹤0.01% 4083
2026
Q2 		$628K Sell
25,620
-2,620
-9% -$47.3K ﹤0.01% 3085
2026
Q1 		$494K Sell
28,240
-9,540
-25% -$184K ﹤0.01% 3192
2025
Q4 		$500K Buy
37,780
+3,222
+9% +$28.6K ﹤0.01% 3846
2025
Q3 		$203K Sell
34,558
-5,403
-14% -$25.3K ﹤0.01% 4283
2025
Q2 		$165K Buy
39,961
+27,234
+214% +$110K ﹤0.01% 4384
2025
Q1 		$47.9K Sell
12,727
-6,064
-32% -$28K ﹤0.01% 4623
2024
Q4 		$109K Buy
18,791
+6,891
+58% +$119K ﹤0.01% 4574
2024
Q3 		$248K Buy
+11,900
New +$238K ﹤0.01% 4190

Other funds holding BIOA

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Sands Capital Ventures
Sands Capital Ventures Arlington, Virginia $695M AUM 31.12% 1-Year Est. Return
Pivotal bioVenture Partners Investment Advisor
Pivotal bioVenture Partners Investment Advisor San Francisco, California $252M AUM 45.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
CM
Cosmic Management West Hollywood, California $327M AUM 21.97% 1-Year Est. Return

Barclays's BIOA Position: Q3 2026 in Review

Barclays reduced its BioAge Labs (BIOA) stake by 11% in Q3 2026, selling an estimated $37.8K and leaving 22,891 shares worth $162K. The position accounts for ﹤0.01% of the portfolio, ranked #4083.

Barclays first reported a position in BIOA in Q3 2024 and has held it in 9 quarters since. The position peaked at $628K in Q2 2026. 104 funds tracked by Wall St. Rank hold BIOA as of Q3 2026.

  • Barclays held 22,891 shares of BioAge Labs worth $162K as of Q3 2026.
  • Barclays sold 2,729 BioAge Labs shares in Q3 2026, an estimated $37.8K.
  • BioAge Labs made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4083 holding.
  • Barclays first reported a position in BioAge Labs in Q3 2024 and has held it in 9 quarters since.
  • Barclays's BioAge Labs position peaked at $628K in Q2 2026.
  • 104 funds tracked by Wall St. Rank held BioAge Labs as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.